Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Director | September 06, 2024 | September 09, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date September 06, 2024 · Filed September 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,651 |
Reported balance
After 2024-09-06 transaction · row 1
1 source rowRow 1 · 2024-09-06 · Gift · Disposed 230,000 · Balance 35,651 |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2022 GRAT | 0 |
Reported balance
After 2024-09-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-06 · Gift · Disposed 302,179 · Balance 0 F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Jonathan W. Ayers 2024 GRAT | 419,574 |
Reported balance
After 2024-09-06 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-06 · Gift · Acquired 419,574 · Balance 419,574 F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Indirectby Ayers Family Trust | 122,605 |
Reported balance
After 2024-09-06 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2024-09-06 · Gift · Acquired 112,605 · Balance 122,605 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2022 GRAT ('2022 GRAT'). The 2022 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
F2: The reporting person is the grantor and trustee of the Jonathan W. Ayers 2024 GRAT ('2024 GRAT'). The 2024 GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,846 | $293.78 | $2,011,196.66 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 13 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 818,188 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $293.06 to a high of $294.035 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,406 | $292.71 | $411,543.23 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 825,034 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $292.00 to a high of $292.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $290.16 | $29,016.00 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,440 Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 805 | $289.48 | $233,034.78 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,540 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $289.02 to a high of $289.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 634 | $288.43 | $182,864.94 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,345 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $288.00 to a high of $288.99 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,042 | $295.02 | $2,077,501.97 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 827,979 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $294.56 to a high of $295.44 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 8,104 | $293.94 | $2,382,070.31 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 835,021 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $293.50 to a high of 294.50 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,000 | $293.04 | $879,120.30 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 843,125 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $292.48 to a high of $293.48 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $291.46 | $29,146.00 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,125 Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 100 | $290.35 | $29,035.00 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,225 Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 900 | $289.52 | $260,564.49 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,325 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $289.04 to a high of $290.02 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 758 | $288.50 | $218,682.47 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,225 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $288.00 to a high of $289.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 19, 2020 Filed Feb 24, 2020 22:51 UTC Amendment | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,021 | $288.00 | $294,048.00 |
DisclosureSEC source: 0001567619-20-004734 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 847,983 Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,100 | $288.98 | $317,878.00 |
DisclosureSEC source: 0001567619-20-004492 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849,004 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $288.77 to a high of 289.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,779 | $288.17 | $800,828.04 |
DisclosureSEC source: 0001567619-20-004492 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850,104 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $287.75 to a high of $288.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 19,035 | $287.07 | $5,464,360.32 |
DisclosureSEC source: 0001567619-20-004492 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 852,883 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $286.74 to a high of $287.7350 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 22:26 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 17,086 | $286.23 | $4,890,512.11 |
DisclosureSEC source: 0001567619-20-004492 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 871,918 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $285.73 to a high of $286.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 14, 2020 Filed Aug 18, 2020 21:08 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 200 | $383.44 | $76,688.40 |
DisclosureSEC source: 0001567619-20-015707 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 810,723 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $383.247 to a high of $383.637 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 726 | Not disclosed Strike: $251.58 | Not disclosed |
DisclosureSEC source: 0001567619-19-022598 · doc1.xml · derivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726 Underlying: Common Stock · 726 shares Expires 2029-11-30 F3 · derivative.exercise_price: November 29, 2019 closing price of Issuer common stock on the NASDAQ Global Select Market. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 6, 2020. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantDeferred Stock Unit · Derivative | 214 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-022598 · doc1.xml · derivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214 Underlying: Common Stock · 214 shares Expires not disclosed F1 · security: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director effective November 1, 2019 until the 2020 annual meeting of stockholders. F2 · derivative.exercise_price: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F5 · price: Not applicable. F2 · derivative.exercise_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. F2 · derivative.expiration_date: Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2020 annual meeting of stockholders or May 6, 2020, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors. Read SEC document |
| November 18, 2019 Filed Feb 14, 2020 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 3,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004074 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 889,004 Read SEC document |
| November 18, 2019 Filed Feb 14, 2020 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 17,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004074 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 892,864 Read SEC document |
| November 18, 2019 Filed Feb 14, 2020 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004074 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 910,164 Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 20,353 | $254.23 | $5,174,257.71 |
DisclosureSEC source: 0001567619-19-021616 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926,964 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $254.01 to a high of $254.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 12, 2019 Filed Nov 14, 2019 22:06 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 15,647 | $253.83 | $3,971,682.70 |
DisclosureSEC source: 0001567619-19-021616 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 947,317 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $253.00 to a high of $254.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,018 | $264.49 | $798,219.35 |
DisclosureSEC source: 0001567619-19-021041 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962,964 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $264.26 to a high of $265.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 12,765 | $263.39 | $3,362,196.33 |
DisclosureSEC source: 0001567619-19-021041 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965,982 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $263.195 to a high of $264.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 22,007 | $262.72 | $5,781,665.84 |
DisclosureSEC source: 0001567619-19-021041 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 978,747 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $262.19 to a high of $263.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 11,794 | $266.54 | $3,143,538.56 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,754 F10 · price: Represents the weighted average price of the shares sold ranging from a low of 266.1150 to a high of $267.05 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,839 | $265.38 | $1,018,811.48 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 9 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,012,548 F9 · price: Represents the weighted average price of the shares sold ranging from a low of 265.00 to a high of $266.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 05, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,300 | $277.87 | $361,232.95 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,016,387 F8 · price: Represents the weighted average price of the shares sold ranging from a low of 277.55 to a high of $277.95 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 53,820 | Not disclosed Strike: $45.84 | Not disclosed |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · derivative · entry 12 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 53,820 shares Expires 2020-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · shares: The number of derivative securities has been revised to reflect the current number available for the reported transaction. F13 · price: Not applicable. F12 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,984 | $281.74 | $840,702.01 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017,687 F7 · price: Represents the weighted average price of the shares sold ranging from a low of 281.515 to a high of $281.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,402 | $280.08 | $952,833.86 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,020,671 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $280.05 to a high of $280.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,891 | $279.43 | $528,408.37 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,024,073 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $279.01 to a high of $280.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,247 | $280.47 | $1,191,137.40 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 4 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,964 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $280.17 to a high of $280.63 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 26,198 | $279.72 | $7,328,222.45 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,030,211 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $279.16 to a high of $280.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 23,375 | $278.90 | $6,519,257.11 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,056,409 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $278.155 to a high of $279.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 22:16 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 53,820 | $45.84 | $2,467,108.80 |
DisclosureSEC source: 0001567619-19-020529 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Senior Advisor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,079,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 22 shares of common stock acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2019. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $45.84 | Not disclosed |
DisclosureSEC source: 0001567619-19-016394 · doc1.xml · derivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,820 Underlying: Common Stock · 10,000 shares Expires 2020-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,522 | $273.35 | $416,038.40 |
DisclosureSEC source: 0001567619-19-016394 · doc1.xml · nonDerivative · entry 3 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,942 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $273.26 to a high of $273.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 8,478 | $272.64 | $2,311,447.85 |
DisclosureSEC source: 0001567619-19-016394 · doc1.xml · nonDerivative · entry 2 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,464 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $272.25 to a high of $273.25 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10,000 | $45.84 | $458,400.00 |
DisclosureSEC source: 0001567619-19-016394 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Feb 14, 2020 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GiftCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004074 · doc1.xml · nonDerivative · entry 1 AYERS JONATHAN W · CIK 0001184149 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 911,964 Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $45.84 | Not disclosed |
DisclosureSEC source: 0001567619-19-015977 · doc1.xml · derivative · entry 11 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,820 Underlying: Common Stock · 10,000 shares Expires 2020-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · price: Not applicable. F8 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 10,000 | $264.38 | $2,643,798.00 |
DisclosureSEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 8 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,942 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $264.31 to a high of $265.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 10,000 | $45.84 | $458,400.00 |
DisclosureSEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 7 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,035,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 10,000 | Not disclosed Strike: $45.84 | Not disclosed |
DisclosureSEC source: 0001567619-19-015977 · doc1.xml · derivative · entry 10 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,820 Underlying: Common Stock · 10,000 shares Expires 2020-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · price: Not applicable. F8 · derivative.exercise_date: Grant of option to buy 55,910 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2014 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,000 | $261.67 | $523,338.20 |
DisclosureSEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 6 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,025,942 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $261.36 to a high of $262.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 22:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,200 | $260.39 | $1,093,629.60 |
DisclosureSEC source: 0001567619-19-015977 · doc1.xml · nonDerivative · entry 5 AYERS JONATHAN W · CIK 0001184149 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,027,942 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $260.07 to a high of $261.03 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.